NRx Pharmaceuticals, Inc.

Contributing Author

Recent Articles by NRx Pharmaceuticals, Inc.

Sep-15	NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine NRXP GlobeNewswire
Sep-14	GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) NRXP GlobeNewswire
Sep-11	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System NRXP GlobeNewswire
Sep-08	NRx Pharmaceuticals to Participate in Upcoming Investor Conferences NRXP GlobeNewswire
Aug-17	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET NRXP GlobeNewswire
Aug-07	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans NRXP +15.86% NRXP -6.42% GlobeNewswire
Aug-07	FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval NRXP +15.86% GlobeNewswire
Jun-25	NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute NRXP GlobeNewswire
Jun-25	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System NRXP GlobeNewswire
Jun-22	NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression NRXP GlobeNewswire
Jun-05	NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. NRXP GlobeNewswire
Jun-04	NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option NRXP GlobeNewswire
Jun-03	NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock NRXP -12.34% GlobeNewswire
Jun-02	NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock NRXP GlobeNewswire
May-28	NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 NRXP GlobeNewswire
May-27	NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System NRXP GlobeNewswire
May-18	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update NRXP -5.03% GlobeNewswire
May-14	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update NRXP +8.81% GlobeNewswire
May-07	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality NRXP GlobeNewswire
May-05	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine NRXP GlobeNewswire
Apr-22	NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program NRXP GlobeNewswire
Apr-20	NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality NRXP +25.49% GlobeNewswire
Apr-15	NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications NRXP GlobeNewswire
Apr-13	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer NRXP GlobeNewswire
Apr-06	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application NRXP GlobeNewswire
Mar-30	Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network NRXP GlobeNewswire
Mar-24	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress NRXP +20.34% GlobeNewswire
Mar-19	NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 NRXP GlobeNewswire
Mar-17	NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application NRXP -6.25% GlobeNewswire
Mar-16	NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRXP +11.83% GlobeNewswire
Mar-09	HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD NRXP GlobeNewswire
Mar-02	NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer NRXP GlobeNewswire
Feb-17	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting NRXP GlobeNewswire
Jan-16	NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date NRXP +5.58% GlobeNewswire
Jan-14	NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRXP GlobeNewswire
Jan-05	NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions NRXP -8.02% GlobeNewswire
Dec-18	NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion NRXP GlobeNewswire
Dec-03	NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation NRXP +6.17% GlobeNewswire
Dec-02	NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE, a Preservative-Free IV Ketamine NRXP -5.02% GlobeNewswire
Dec-02	NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call NRXP -5.02% GlobeNewswire
Dec-01	NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference NRXP GlobeNewswire
Nov-17	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update NRXP -15.26% GlobeNewswire
Nov-12	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025 NRXP +6.02% GlobeNewswire
Nov-10	HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health NRXP GlobeNewswire
Oct-20	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director NRXP GlobeNewswire
Oct-06	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference NRXP GlobeNewswire
Sep-29	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE, Preservative-Free IV Ketamine NRXP +10.17% GlobeNewswire
Sep-24	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine NRXP GlobeNewswire
Sep-08	HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics NRXP GlobeNewswire
Sep-03	NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th NRXP GlobeNewswire
Sep-02	UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office NRXP +12.07% GlobeNewswire
Sep-02	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital NRXP +12.07% GlobeNewswire
Aug-27	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine) NRXP GlobeNewswire
Aug-18	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update NRXP GlobeNewswire

NRx Pharmaceuticals, Inc.

Recent Articles by NRx Pharmaceuticals, Inc.

Upgrade your Finviz experience